Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Dexcom can capitalise on its new algorithm technology, but is now enmeshed in a tangled web of partnerships.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Battle of the algorithms.